Literature DB >> 24032056

CUA-CUOG guidelines for the management of castration-resistant prostate cancer (CRPC): 2013 update.

Fred Saad1, Sebastien Hotte, Charles Catton, Darrel Drachenberg, Antonio Finelli, Neil Fleshner, Martin Gleave, Anil Kapoor, Wassim Kassouf, Andrew Loblaw, Scott North, Nawaid Usmani, Kim N Chi.   

Abstract

Entities:  

Year:  2013        PMID： 24032056      PMCID： PMC3758937          DOI： 10.5489/cuaj.1542

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  31 in total

1.  Prednisone monotherapy in asymptomatic hormone refractory prostate cancer.

Authors:  Daniel Y C Heng; Kim N Chi
Journal:  Can J Urol       Date:  2006-12       Impact factor: 1.344

2.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

3.  First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?

Authors:  Jorg Michels; Trina Montemurro; Nevin Murray; Christian Kollmannsberger; Kim Nguyen Chi
Journal:  Cancer       Date:  2006-03-01       Impact factor: 6.860

4.  Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial.

Authors:  A T Porter; A J McEwan
Journal:  Semin Oncol       Date:  1993-06       Impact factor: 4.929

5.  Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Authors:  Chris Tran; Samedy Ouk; Nicola J Clegg; Yu Chen; Philip A Watson; Vivek Arora; John Wongvipat; Peter M Smith-Jones; Dongwon Yoo; Andrew Kwon; Teresa Wasielewska; Derek Welsbie; Charlie Degui Chen; Celestia S Higano; Tomasz M Beer; David T Hung; Howard I Scher; Michael E Jung; Charles L Sawyers
Journal:  Science       Date:  2009-04-09       Impact factor: 47.728

6.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

Authors:  Daniel P Petrylak; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Donna Berry; Carol Moinpour; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

7.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

8.  Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group.

Authors:  G O N Oosterhof; J T Roberts; Th M de Reijke; S A Engelholm; S Horenblas; H von der Maase; N Neymark; M Debois; L Collette
Journal:  Eur Urol       Date:  2003-11       Impact factor: 20.096

9.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Authors:  Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

Review 10.  Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.

Authors:  Terrence H Diamond; Celestia S Higano; Matthew R Smith; Theresa A Guise; Frederick R Singer
Journal:  Cancer       Date:  2004-03-01       Impact factor: 6.860
View more
  7 in total

1.  CUA-CUOG CRPC Guidelines: A useful compendium.

Authors:  Joseph L Chin
Journal:  Can Urol Assoc J       Date:  2015 Mar-Apr       Impact factor: 1.862

2.  Prostate cancer: alkaline phosphatase velocity in nonmetastatic CRPC.

Authors:  Yao Zhu; Ding-Wei Ye
Journal:  Nat Rev Urol       Date:  2014-08-05       Impact factor: 14.432

Review 3.  [Not Available].

Authors:  Imad Ziouziou; Tariq Karmouni; Khalid El Khader; Abdellatif Koutani; Ahmed Iben Attya Andaloussi
Journal:  Can Urol Assoc J       Date:  2014-03       Impact factor: 1.862

4.  Treatment patterns and trends in patients dying of prostate cancer in Quebec: a population-based study.

Authors:  A Dragomir; J Rocha; M Vanhuyse; F L Cury; W Kassouf; J Hu; A G Aprikian
Journal:  Curr Oncol       Date:  2017-08-31       Impact factor: 3.677

5.  Survival analysis of patients with biochemical relapse after radical prostatectomy treated with androgen deprivation: Castration-resistance influential factors.

Authors:  Rubén Algarra; Mateo Hevia; Antonio Tienza; Imanol Merino; José María Velis; Javier Zudaire; José Enrique Robles; Ignacio Pascual
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

6.  Drug costs in the management of metastatic castration-resistant prostate cancer in Canada.

Authors:  Alice Dragomir; Daniela Dinea; Marie Vanhuyse; Fabio L Cury; Armen G Aprikian
Journal:  BMC Health Serv Res       Date:  2014-06-13       Impact factor: 2.655

7.  Clinical management and burden of prostate cancer: a Markov Monte Carlo model.

Authors:  Chiranjeev Sanyal; Armen Aprikian; Fabio Cury; Simone Chevalier; Alice Dragomir
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.